Category - Markets

Roth Capital Partners launched coverage of Cutera (NASDAQ:CUTR) with a “buy” rating and $32 price target. The stock closed at $24.50 on June 23. Cutera has built a comprehensive product portfolio, offering multiple...

H.C. Wainwright initiated coverage of Antares Pharma (NASDAQ:ATRS) with a “buy” rating and $5 price target. The stock closed at $3.01 on June 22. Analyst Corey Davis writes that Antares has been a long leader in complex...

H.C. Wainwright launched coverage of Achaogen (NASDAQ:AKAO) with a “buy” rating and $29 price target. The stock closed at $22.11 on June 14. Achaogen has a pipeline of novel antibiotics for serious, hard-to-treat, multi...

H.C. Wainwright initiated coverage of XOMA (NASDAQ:XOMA) with a “buy” rating and $15 price target. The stock closed at $6.86 on June 12th. XOMA owns several premier antibody discovery and development platforms that...

H.C. Wainwright initiated coverage of ZIOPHARM Oncology (NASDAQ:ZIOP) with a “buy” rating and $9.50 price target. The stock closed at $5.85 on May 31. Anchored by two cutting-edge technologies, ZIOPHARM is focused on...

William Blair initiated coverage of Ovid Therapeutics (NASDAQ:OVID) with an “outperform” rating and fair value estimate of $28. The stock closed at $14.57 on May 26. Ovid is focused on rare neurological disorders. Its...

William Blair launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and fair value estimate of $46. The stock closed at $23.79 on May 26. Biohaven is developing a portfolio of...

H.C. Wainwright initiated coverage of Vanda Pharmaceuticals (NASDAQ:VNDA) with a “buy” rating and $18 price target. The stock closed at $14.05 on May 26. “We think Vanda now has a solid base business, with both Fanapt...

William Blair initiated coverage of Albany Molecular Research (NASDAQ:AMRI) with an “outperform” rating. The stock closed at $17.31 on May 19. Albany Molecular is a leading provider of discovery and formulation...

Leerink launched coverage of Verona Pharma (NADAQ:VRNA; AIM:VRP) with a “buy” rating and $22 price target after its recent cross-listing from the London Stock Exchange to NASDAQ. The stock closed at $13.52 on May 19...